Tremelimumab

Drug Profile

Tremelimumab

Alternative Names: Anti CTLA 4 monoclonal antibody-Pfizer; CP-675; CP-675206; Ticilimumab

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Amgen; ARCAGY/GINECO Group; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Fondazione IRCCS Istituto Nazionale dei Tumori; Grupo Espanol de Tumores Neuroendocrinos; Immunocore; Institute Gustave-Roussy; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Health and Medical Research Council; Northwestern University; Pfizer; Seoul National University Hospital; University of Maryland Greenbaum Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Hepatocellular carcinoma; Mesothelioma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
  • Phase II Breast cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Germ cell and embryonal neoplasms; Glioblastoma; Lung cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma
  • Phase I/II Colorectal cancer; Malignant melanoma; Oesophageal cancer
  • Phase I Diffuse large B cell lymphoma; Oropharyngeal cancer; Renal cell carcinoma; Thyroid cancer; Urogenital cancer
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, First-line therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in Canada (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, First-line therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(First-line therapy, Metastatic disease, Monotherapy, Recurrent, Second-line therapy or greater) in Canada (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top